Palatin Technologies (PTN)
(Real Time Quote from BATS)
$1.79 USD
-0.03 (-1.65%)
Updated Apr 29, 2024 02:32 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Brokerage Reports
0 items in cart
Palatin Technologies, Inc. [PTN]
Reports for Purchase
Showing records 181 - 194 ( 194 total )
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
AZD2820 Discontinued; No Surprises; Focus Remains on FSD
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Hiccup, Likely Temporary, for AZD2820 Study; Target to $4.75
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
F3Q12 Results; Expect Results from 2 Studies by Year End
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Positive FDA AdCom Vote for Lorcaserin; We See Positive Impact for Palatin
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Transferring Coverage; Rating, PT and Estimates Under Review
Provider: Roth Capital Partners, Inc.
Analyst: MARTIN J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
F2Q Results, Completing Phase IIb Enrollment, Obesity Program Advancing
Provider: Roth Capital Partners, Inc.
Analyst: MOSKOWITZ D